Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.69−0.02 (-3.12%)
Close on Nov 13, 2026Market cap $26.13MP/E –Yield –
Metagenomi Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Metagenomi Therapeutics's enterprise value was -$92.13M on Nov 11, 2026, against -$118.39M a year earlier. Over the last 3 years it ranged from -$252.53M to -$76.12M, with a median of -$139.47M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$92.13M | – |
| 2025 | Dec 31, 2025 | -$123.27M | – |
| 2024 | Dec 31, 2024 | -$139.47M | – |
See a number that looks wrong?